Breast Cancer Evolution During Neoadjuvant Systemic Therapy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRoyal Marsden NHS Foundation Trust
About this trial
BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before surgery. In certain cases, MRI scans and stool samples will also be obtained before and during treatment. The samples collected from this study will be used for molecular and genetic research to understand why some cancers respond very well to anticancer treatments, and some do not, develop novel ways of accurately measuring response during treatment, as well as identify which patients are at a higher risk of the cancer coming back after surgery.
Eligibility criteria
Qualifiers
Histologically confirmed non-metastatic invasive breast cancer.
Be suitable for, but have not commenced, neoadjuvant chemotherapy, targeted therapy, or immunotherapy.
If HER2-, suitable for treatment with upfront taxane chemotherapy. If HER2+, suitable for treatment with anti-HER2 targeted therapy.
Be aged 18 years and over.
Disqualifiers
Metastatic breast cancer at diagnosis.
Treatment with neoadjuvant endocrine therapy only.
Presence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov